Loading stock data…
Alcon Inc. (ALC)
$68.12+0.91 (+1.35%)
Market OpenUpdated 3:01 PM EDT
Alcon Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alcon Inc. in the Healthcare sector is trading at $68.12 with a market capitalization of $31.3B. Wall Street consensus targets $87.32 (15 analysts), implying a +28.2% move over the next 12 months. The stock is currently 26% below its 52-week high of $91.86, remaining 8.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +28.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.71B↓ | $2.72B↑ | $2.61B↑ | $2.60B↑ | $2.47B |
| Gross Profit | $1.52B↑ | $1.52B↑ | $1.46B↑ | $1.39B↑ | $1.38B |
| Operating Income | $292.00M↓ | $313.00M↓ | $332.00M↑ | $247.00M↓ | $468.00M |
| Net Income | $189.00M↓ | $217.00M↓ | $237.00M↑ | $176.00M↓ | $350.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
38.46
Beta
Defensive asset. Lower volatility than the S&P 500.
0.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.53%
ROE
Average efficiency. Growth may require heavy reinvestment.
3.70%
Volume
Today's trading volume
659,860
Recent News
Ecolab Gears Up to Report Q2 Results: How to Play the Stock?
ECL's Q2 results are likely to benefit from strong growth engines and pricing gains, but elevated input costs may test margins and earnings momentum.
IQVIA Gears Up to Report Q2 Earnings: What's in the Offing?
IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.
Reasons to Retain Align Technology Stock in Your Portfolio for Now
ALGN's global expansion and iTero innovations support growth, but can they offset currency headwinds and macro pressures?
Can Acute Care Strength Offset Universal Health's Rising Q2 Costs?
UHS heads into Q2 with higher admissions and revenue growth expected, but rising labor and operating costs may limit earnings upside.
Alcon (SWX:ALC) Stock Looks Undervalued On Cash Flow But Fair On Earnings
Alcon stock sits at an interesting junction, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to a large gap to the current share price while the broader valuation checks suggest neither a clear bargain nor a clear overvaluation. Over the past 3 years, Alcon shareholders have seen the stock decline about 23.7%, which puts more attention on whether today’s price properly reflects the company’s long term prospects. Future growth in cash flows from Alcon’s eye care...